Article Text

Download PDFPDF

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
  1. Gro Gausdal1,
  2. David R Micklem1,
  3. Magnus Blø1,
  4. Austin Rayford1,2,
  5. Dina Alzhanova3,
  6. Noëlly Madeleine1,
  7. Josephine Amalia Taverna4,
  8. Chia-Nung Hung4,
  9. Rolf A Brekken3,
  10. Michael Chisamore5,
  11. Claudia Gorcea-Carson6,
  12. Cristina Oliva6 and
  13. Nigel McCracken6
  1. 1BerGenBio ASA, Bergen, Norway
  2. 2University of Bergen, Bergen, Hordaland, Norway
  3. 3University of Texas Southwestern Medical Center, Dallas, TX, USA
  4. 4University of Texas Health Science Center, San Antonio, TX, USA
  5. 5Merck and Co., Inc., Rahway, NJ, USA
  6. 6BerGenBio Ltd, Oxford, Oxfordshire, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background In NSCLC, mutations in LKB1/STK11, KEAP1, SMARCA4, and KRAS are associated with unfavorable treatment outcomes, regardless of treatment modality.1–4 These mutations shape tumor survival, mediate enhanced tolerance to oxidative and metabolic stress and sustain an immune suppressed tumor microenvironment (TME) resulting in reduced therapeutic efficacy.5–8 The receptor tyrosine kinase AXL is a poor prognostic biomarker in NSCLC. Activated in response to cellular stress, AXL drives drug resistance, metastasis and an immune-suppressive and tumor-promoting TME.9–12 Bemcentinib (BEM), a highly selective oral AXL inhibitor, enhances anti-tumor effects of immune-check-point inhibition (ICI) in pre-clinical NSCLC models harboring mutations in STK11, KEAP1, SMARCA4 and KRAS.9 In the BGBC008 ph2 open-label, single-arm study of BEM + pembrolizumab (PEM) in 2L NSCLC following platinum-based chemotherapy and/or ICI, the BEM+PEM combination was well tolerated and efficacious compared to historical controls.14 We present here sub-mutational analyses of patients from BGBC008, specifically those with STK11, KEAP1, SMARCA4, and KRAS mutations and those characterized by functional STK11 loss as determined by a transcriptional signature (STK11LOSS).15

Methods Exploratory analyses assessed AXL and PD-L1 expression by immunohistochemistry (IHC), mutations by whole exome sequencing (WES) and STK11LOSS by RNA sequencing. Association between mutational status and median overall survival (mOS), median progression-free survival (mPFS) and PD-L1 status were included. PD-L1 negativity (PD-L1-ve) was defined as IHC tumor proportion score (TPS)<1. AXL expression was scored in tumor (H-score) and immune cells (percent AXL+ve immune cells/tumor area). Longitudinal single-cell proteomic analysis of peripheral blood mononuclear cells (PBMCs) by mass cytometry is ongoing.

Results Of the 90 evaluable patients in the BGBC008 study, 56 pts were subjected to WES. The correlation between mutational status and clinical efficacy, as well as PD-L1 status are reported in table 1. Data indicate that AXL is present on the immune and/or tumor cells in 87–100 % of patients harboring mutations associated with poorer outcome in NSCLC. BEM+ PEM induces similar or better survival outcome in pts harboring mutations compared to wild-type (WT). Encouragingly, better mPFS in KRASmut pts compared to KRASWT regardless of the type of KRASmut or co-mutational status. A higher incidence of -PD-L1-ve status was seen in patients harbouring STK11mut and KEAP1mut as well as STK11LOSScompared to WT.

Conclusions In 2L, BEM+PEM demonstrated survival benefit in patients harboring mutations associated with poorer response to 1L platinum-based chemotherapy and/or ICI supporting the benefit of targeting AXL in patients with an immune/suppressed TME.

Acknowledgements Thank you to all the patients and their families, investigators and study coordinators who participated in and supported this study. The study was performed in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Trial Registration BGBC008 trial (NCT03184571)


  1. Garassino MC, Gadgeel S, Novello S,. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clin Res Rep., 2022 Nov 8;4(1):100431.

  2. Alessi JV, Elkrief A, Ricciuti B,. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. JTO. 2023 Jun;18(6):731−743.

  3. Skoulidis F, Goldberg ME, Greenawalt DM,. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Cancer Discov. 2018 Jul;8(7):822−835.

  4. Ricciuti B., Kathryn C. Arbour MD,. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. JTO. 2022 Mar;17(3):399−410.

  5. Koyama S, Akbay EA, Li YY,. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res., 2016;76(5):999–1008.

  6. Watterson, A., Coelho, M.A. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Commun Signal 2023;21: 45.

  7. Pons-Tostivint E, Luga A, Fontenau JF., STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact Cells 2021 Nov 11;10(11):3129.

  8. Tian Y, Xu L, Li X., SMARCA4: Current status and future perspectives in non-small-cell lung cancer Cancer Lett. 2023 Feb 1;554:216022.

  9. Li H, Liu Z, Liu L., AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells Cell Rep Med., 2022 Mar 15;3(3).

  10. Wu F, Li J, Jang C,. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int. J. Clin. Exp. Pathol., 2014, 7, 6653–6661.

  11. Byers LA, Diao L, Wang J., An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor Resistance. Clin Cancer Res., 2013 Jan 1;19(1):279−90.

  12. Liang Z, Yang Y, Wu X, GAS6/Axl is associated with AMPK activation and attenuates H2O2-induced oxidative stress Apoptosis., 2022 Dec 29

  13. Blø M, Rayford A, Madeleine N., AXL as a therapeutic target in STK11 mutant NSCLC. Cancer Res. 2023; 83(7_Supplement): 3245.

  14. Felip E, Krebs M, Costa EC,. Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571). Poster ESMO 2023.

  15. Kaufman JM, Amann JM, Park K., LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT JTO., 2014 Jun;9(6):794−804.

Ethics Approval This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and consistent with Good Clinical Practices (GCP) and applicable regulatory requirements. The protocol, the patient information and consent form and other relevant study documentation were approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) for each study center before initiation of the study.

Consent Patients provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits of treatment prior to commencing the study Screening procedures.

Abstract 598 Table 1

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.